Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study. This is an ASCO Meeting Abstract from the 2021 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results